S1P Receptor

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S7176 SKI II <1 mg/mL 61 mg/mL 61 mg/mL
S7177 PF-543 <1 mg/mL 93 mg/mL 93 mg/mL
S7174 Opaganib (ABC294640) <1 mg/mL 76 mg/mL 28 mg/mL
S5002 Fingolimod (FTY720) HCl 69 mg/mL 69 mg/mL 69 mg/mL
S7182 JTE 013 <1 mg/mL 81 mg/mL 34 mg/mL
S7952 Ozanimod (RPC1063) <1 mg/mL 81 mg/mL 10 mg/mL
S8241 Ponesimod <1 mg/mL 92 mg/mL 92 mg/mL
S7179 BAF312 (Siponimod) <1 mg/mL 100 mg/mL 44 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


SKI II is a highly selective and non ATP-competitive sphingosine kinase (SphK) inhibitor with IC50 of 0.5 μM, while exhibiting no inhibitory action on other kinases including PI3K, PKCα and ERK2.



PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform.


Opaganib (ABC294640)

Opaganib (ABC294640) is an orally bioavailable and selective sphingosine kinase-2 (SphK2) inhibitor with IC50 of approximately 60 μM. Phase 1/2.


Fingolimod (FTY720) HCl

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.


JTE 013

JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.


Ozanimod (RPC1063)

Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.



Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.


BAF312 (Siponimod)

BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.